SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 28, 2025	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Summary of Significant Accounting Policy [Line Items]
Long-term equity investments		$ 20,908		$ 20,974
Marketable securities, fair value		$ 21,860		26,774
Estimated useful life (in years)		3 years
Decrease in fair value of royalty monetization liability				30,000
Contribution amount to retirement plan		$ 70	$ 100
Ligand Agreement
Summary of Significant Accounting Policy [Line Items]
Decrease in fair value of debt		$ 0
Pension Plan, Matching Scenario One
Summary of Significant Accounting Policy [Line Items]
Percentage of matching contribution from employer		100.00%
Percentage of eligible employees' contribution		3.00%
Pension Plan, Matching Scenario Two
Summary of Significant Accounting Policy [Line Items]
Percentage of matching contribution from employer		50.00%
Pension Plan, Matching Scenario Two | Maximum
Summary of Significant Accounting Policy [Line Items]
Percentage of eligible employees' contribution		5.00%
Pension Plan, Matching Scenario Two | Minimum
Summary of Significant Accounting Policy [Line Items]
Percentage of eligible employees' contribution		3.00%
Level 2
Summary of Significant Accounting Policy [Line Items]
Marketable securities, fair value		$ 21,900		26,800
Money Market Funds and Short-term Investments | Level 1
Summary of Significant Accounting Policy [Line Items]
Fair value assets		18,900		25,800
Gensaic, Inc
Summary of Significant Accounting Policy [Line Items]
Long-term equity investments		5,100		5,100
Graviton Bioscience Corporation
Summary of Significant Accounting Policy [Line Items]
Long-term equity investments		15,800		15,800
Payments for long term investments		10,000
Cumulative measurement adjustment of long term investment		$ 5,800	$ 4,200
Marinus Therapeutics, Inc
Summary of Significant Accounting Policy [Line Items]
Long-term equity investments				$ 100
Marinus Pharmaceuticals, Inc
Summary of Significant Accounting Policy [Line Items]
Sale of long-term investment	$ 70
Ligand Pharmaceuticals Incorporated | Purchase Agreement
Summary of Significant Accounting Policy [Line Items]
Share of royalties and milestones		13.00%